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a b s t r a c t
Background: Current risk prediction models in acute coronary syndrome (ACS) patients undergoing PCI
are mathematically complex. This study was undertaken to assess the accuracy of a modified
CHA2DS2-VASc score, comprised of easily accessible clinical factors in predicting adverse events.
Methods: The National Inpatient Sample (NIS) was queried for ACS patients who underwent PCI between
2010 and 2014. We developed a modified CHA2DS2-VASc score for risk prediction in ACS patients.
Multivariate mixed effect logistic regression was utilized to study the adjusted risk for adverse outcomes
based on the score. The primary outcome evaluated was in-hospital mortality. Secondary outcomes
assessed were stroke, respiratory failure, acute kidney injury, all-cause bleeding, pacemaker insertion,
vascular complications, length of stay and cost.
Results: There were 252,443 patients admitted with ACS included. Mean age was 62 ± 12 years. The mean
CH3A2DS-VASc score was 1.6 ± 1.6. The in-hospital mortality rate was 2.5%. CH3A2DS-VASc score was
highly correlated with increased rate of mortality and all secondary outcomes. ROC curve analysis for
association of CH3A2DS-VASc score with mortality demonstrates that area under the curve
(AUC) = 0.83 (95%C: 0.82–0.84). Stepwise increases in CH3A2DS-VASc score correlated with incremental
risk, and total score was an independent predictor of mortality (adjusted OR: 1.99 (95%CI: 1.96–2.03)
p < 0.001) and all secondary outcomes.
Conclusion: This study supports the applicability of the CH3A2DS-VASc score as an accurate risk prediction
model for ACS patients undergoing PCI and could supplantmore complicatedmodels for quality assurance.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Current risk prediction models in acute coronary syndrome
(ACS) patients undergoing percutaneous coronary intervention
(PCI) have several purposes, including the assessment of program-
matic and operator quality, and providing advice and assistance in
clinical decision making [1,2]. However, they are not often used in
practice because they require knowledge of an intricate group of
variables and a complex computer-based algorithm to calculate
risk. Their computation requires a specialized formula incorporat-
ing numerous clinical and laboratory parameters that are not
captured in some databases. In fact, the value of the models is
determined entirely by the specific variables collected by the spon-
soring agency or study [3,4]. Moreover, some risk prediction mod-
els are derived in specific subsets of ACS, and are often quite
dependent on cardiogenic shock to dominate the algorithm [1,2].
The purpose of this study is to investigate the accuracy of apply-
ing the CH3A2DS-VASc score as a simple-to-use prediction model
applicable to all ACS patients for in-hospital mortality and other
adverse events. The modified CHA2DS2-VASC score requires a sim-
ple calculation based upon easily accessible clinical factors.
https://doi.org/10.1016/j.ijcha.2020.100532
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2. Methodology
This study was conducted using The National Inpatient Sample
(NIS) of the Health Care Utilization Project (HCUP) sponsored by
the Agency for Healthcare Research and Quality. NIS is a publicly
available national registry that receives data from all USA commu-
nity hospital discharges. The basic details of the registry database
utilized in this study have previously been published.[5] In brief,
the NIS includes administrative as well as demographic data from
a 20% sample of inpatient hospitalizations in the United States. NIS
provides hospitalization information for over 7 million hospital
stays each year with weighted estimate of more than 35 million
hospitalizations annually.
2.1. Patient population
The NIS database population is derived from patients through-
out the USA in diverse practice settings. All patients aged  18
who were admitted for ACS (including unstable angina, non-Q
myocardial infarction and STEMI) who underwent PCI on that
admission between 2010 and 2014 were included. These patients
were identified utilizing the International Classification of Dis-
eases—Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis
codes (Suppl. Table 1-2). Patients with atrial fibrillation or flutter
were excluded. Patient records with missing values were excluded;
accordingly, a complete case analysis was performed.
To optimize the original CHA2DS2-VASc score for application to
PCI outcomes in an ACS population, several modifications were
made after initial data analysis. At univariate analysis level, all
components of the original score were predictive of increased mor-
tality in ACS patients except for hypertension and vascular disease.
Exploratory study showed that hypotension and shock correlated
with highest risk for mortality and complications. Accordingly,
hypertension was replaced with either hypotension or cardiogenic
shock and 3 points were assigned to this factor. Similarly, history of
previous stroke was less predictive of adverse outcomes, accord-
ingly only one point was assigned for a previous history of stroke.
The value of the extra points assigned were adjusted based on the
assessment of model fit per each point added. The general use of
VASc component of the original score was not predictive of adverse
outcomes, as more than 95% of study population had a vascular
disease. Accordingly, the VASc component of the original score
was limited to the presence of peripheral vascular disease which
was predictive of adverse outcomes. The final CH3A2DS-VASc score
was calculated by assigning one point each for a prior history of
congestive heart failure (CHF), age  65 years, age  75 years, dia-
betes mellitus, peripheral vascular disease, prior history of stroke
and three points for hypotension or cardiogenic shock (max 9
points). Female gender was dropped from the model as was not
significantly contributing to the score (suppl. Table 3, Suppl.
Fig. 3). Patients were divided into three CH3A2DS-VASc score cate-
gories; low (0–3), intermediate (4–6) and high (7–9).
2.2. Statistical analysis
Categorical variables were compared using Pearson’s chi-square
(v2) test and presented as percentages. Continuous variables with
normal distribution are expressed as mean ± standard deviation
and compared using ANOVA tests. Continuous variables with
skewed distribution are expressed as median with inter-quartile
ranges and compared by using the Wilcoxon rank-sum test.
The cost for each inpatient hospitalizationwasmeasured for each
patient bymultiplying the total hospital chargewith cost-to-charge
ratio. To obtain a standardized cost over the study period, adjusted
cost for each hospitalization year was calculated in terms of the
December 2014 cost after adjusting for the inflation using the Con-
sumer Price Index inflation calculator provided by the United States
Department of Labor [22]. Given the nested observations in the NIS
database, binary outcomes were modeled using a mixed-effect
logisticmodel to account for the potential correlation of observation
within each hospital. A hierarchical model was formed with unique
hospital identification number as random effects in the model.
Potential patient-level factors including demographics, insurance
type and comorbid conditions as well as hospital level factors
including hospital size, teaching status and ownership were
adjusted in the multivariate analysis. The length of stay and total
charges for each hospitalization were modelled with mixed effect
generalized linear regression model with a negative binomial func-
tion to account for over dispersion in length of stay andwith gamma
function to account for positive skewness of the total charges. Odd
ratios with 95% confidence intervals were reported for binary out-
comes and incidence rate ratio referred to as (mean ratios) with
95% confidence intervals for the numeric outcomes. Calculated
mean ratio, represents the increase or decrease in percent of LOS
and cost. [6,7] For example, IRR of 1.17 for LOS represents a 17%
increase inmean LOS for a given variable compared to the reference.
To test model discrimination, receiver-operating characteristic
(ROC) analysis and the area under the curve (AUC) were used to
identify the sensitivity and specificity of the cut-off points for mor-
tality. The optimal cut-off value was defined by Youden’s index
which provides the maximum vertical distance from the line of
equality to the point [x, y] were  represents (1- specificity) and
y represents sensitivity.
Internal validation of the score was evaluated by bootstrapping
with 100 iterations. The differences between the mean of AUCs for
the bootstrap samples and the full dataset were used to calculate
the optimism of the of the original AUCs calculated for both mod-
els. The optimism is a measure for the ability of the model to per-
form in the original data from which it was derived versus a new
test population. A low optimism score correlates with higher
model performance.
Given the large sample, traditional tests would have huge
power to detect minuscule deviations from the perfect fit and tend
to reject the hypothesis of perfect fit, even if the model if the cal-
ibration is acceptable [8]. Accordingly, a graphical method for cal-
ibration was performed by plotting observed vs predicted rates of
mortality. The calibration plot yielded an intercept that measures
the extent to which predictions are either too high or too low
(calibration-in-the-large) by comparing the mean of all predicted
risks with the mean observed risk. An intercept value of 0 would
be considered as an ideal. The slope of the calibration plot would
be equal to 1.0 in the case of a perfect model. The model external
application was evaluated by measuring the AUC and calibration
plot in a random sample of 2000 ACS patients derived from NIS
database of the year 2015. All analyses were performed using
STATA 15 (Stata Corp); a p value < 0.05 was considered significant.
2.3. Outcomes
The primary outcome was all cause in-hospital mortality. Sec-
ondary outcomes were in-hospital complications including stroke,
pacemaker insertion, all-cause bleeding, acute kidney injury, respi-
ratory failure, vascular complications, length of stay and cost.
3. Results
3.1. Participants
Suppl. Fig. 1 illustrates the algorithm used in assessing inclusion
of ACS patient records from the NIS database. There were 252,443
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patients included. Mean age was 62.0 ± 12.7 years. Table 1 summa-
rizes the baseline characteristics of study population including
demographic information, comorbidities and hospital characteris-
tics according to their CH3A2DS-VASc score category.
The mean CH3A2DS-VASc score was 1.6 ± 1.6 (range 1 to 9)
(Suppl. Fig. 2). Diabetes mellitus was the most common individual
component of the CH3A2DS-VASc score in the study population,
and was present in 32.5% of the total population.
Peripheral vascular disease and history of stroke were the least
prevalent components (8.6% and 5.4% of the total population
respectively) (Table 1). Patients with CH3A2DS-VASc score  3 rep-
resented the majority of the study population and accounted for
87.7% of the total. Those with CH3A2DS-VASc score  7 were less
frequent, comprising 0.8% of the total.
3.2. Primary outcome
CH3A2DS-VASc score correlated significantly with increased
mortality risk (Fig. 1). All cause in-hospital mortality was 21.5%
among patients with high CH3A2DS-vasc score compared to
11.6% and 1.1% for medium and low scores respectively
(p < 0.001) (Table 2). Using CH3A2DS-VASc score as a continuous
variable, multivariate analysis showed that higher CH3A2DS-VASc
score was a strong independent predictor of mortality (adjusted
OR: 1.99 (95%CI: 1.96–2.03) p < 0.001) (Table 3). In subgroup anal-
ysis, similar results were observed in both STEMI and NSTEMI
groups (Supp. Table 4).
Each component of CH3A2DS-VASC score was independently
predictive of mortality. The strongest predictive factors for
increased mortality risk were Hypotension/Cardiogenic shock
(AOR: 17.71 (95%CI: 16.78-18.70) p < 0.001, Age  75 (AOR: 3.43
(95%CI: 3.23-3.64) p < 0.001) and congestive heart failure (AOR
3.12 (95%CI: 2.96–3.29) p < 0.001) (Suppl. Table 3).
ROC curve was constructed to determine the predictive accu-
racy of the CH3A2DS-VASc score for in-hospital mortality. The
model had excellent discrimination, with AUC = 0.83 (95%C:
0.82–0.84]) and the optimal cutoff of CH3A2DS -VASc score to pre-
dict increase in mortality was  2 where the Youden Index (J) was
highest (0.54) with a sensitivity of 77% and specificity of 77%
(Fig. 2).
3.3. Secondary outcomes
Overall, higher CH3A2DS-VASc score significantly correlated
with increased risk for all secondary outcomes including, pace-
maker insertion, stroke, all-cause bleeding, acute kidney injury,
Table 1
Comparison of baseline characteristics among ACS with PCI population as per CH3A2DS-VASc score.
Total Low score Medium score High score p-value
N = 252,443 N = 221,462 N = 28,968 N = 2013
CH3A2DS-Vasc score 1.6 (1.6) 1.1 (1.0) 4.6 (0.7) 7.2 (0.4) <0.001
Age in years 62.0 (12.7) 60.7 (12.3) 70.7 (11.9) 79.1 (6.7) <0.001
Indicator of sex <0.001
Male 68.9% 70.5% 57.9% 50.9%
Female 31.1% 29.5% 42.1% 49.1%
Race <0.001
White 76.3% 76.4% 75.3% 74.5%
Other 23.7% 23.6% 24.7% 25.5%
Diabetes Mellitus 32.5% 29.3% 53.6% 78.1% <0.001
Hypertension 69.2% 68.9% 70.5% 76.9% <0.001
Hyperlipidemia 68.7% 69.5% 63.2% 63.6% <0.001
Hypothyroidism 8.1% 7.6% 11.8% 15.1% <0.001
Obstructive sleep apnea 5.8% 5.7% 6.4% 5.0% <0.001
Obesity 15.7% 15.9% 14.0% 11.9% <0.001
History of smoking 48.0% 49.6% 37.2% 26.8% <0.001
Drug abuse 2.6% 2.8% 1.5% 0.5% <0.001
Chronic pulmonary disease 15.4% 14.3% 22.7% 26.2% <0.001
Congestive heart failure 16.3% 11.0% 52.1% 84.6% <0.001
Coronary artery disease 90.4% 90.4% 89.9% 91.4% 0.004
Peripheral vascular disorders 8.6% 6.2% 24.4% 47.5% <0.001
Priory CABG 10.2% 9.4% 15.5% 19.3% <0.001
Prior PCI 14.9% 14.8% 15.9% 15.0% <0.001
Renal failure 10.9% 8.8% 24.9% 40.4% <0.001
History of stroke 5.4% 3.9% 15.5% 28.5% <0.001
Deficiency anemias 9.8% 7.9% 22.6% 35.7% <0.001
Chronic blood loss anemia 0.4% 0.3% 1.1% 1.7% <0.001
Alcohol abuse 3.2% 3.3% 2.6% 1.0% <0.001
Liver disease 1.1% 1.1% 1.4% 1.1% <0.001
Rheumatoid arthritis/collagen vascular diseases 2.1% 2.0% 2.6% 2.7% <0.001
Solid tumor without metastasis 0.9% 0.8% 1.4% 2.1% <0.001
Metastatic cancer 0.4% 0.3% 0.6% 1.0% <0.001
Psychoses 1.9% 1.8% 2.3% 2.4% <0.001
Depression 6.4% 6.3% 7.4% 7.3% <0.001
Number of chronic conditions 6.0 (5.0–8.0) 6.0 (5.0–7.0) 8.0 (6.0–10.0) 10.0 (8.0–12.0) <0.001
Hospital: Location/teaching status <0.001
Rural 6.9% 7.0% 6.2% 5.3%
Urban nonteaching 37.7% 37.8% 37.2% 37.3%
Urban teaching 55.3% 55.2% 56.6% 57.4%
Hospital: Bed size 0.49
Small 9.0% 9.0% 8.9% 8.3%
Medium 23.6% 23.6% 23.2% 23.4%
Large 67.5% 67.4% 67.8% 68.3%
Data are presented as mean (SD) and median (IQR) for continuous measures, and % for categorical measures.
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respiratory failure, vascular complications, length of stay and
cost (Fig. 1, Suppl. Fig. 4). Table 2 summarizes the rate of each
complication according to CH3A2DS-VASc score group category.
On multivariate analysis after accounting for potential con-
founders, CH3A2DS-VASc score was an independent predictor
for increased risk for respiratory failure with adjusted odd ratio
(AOR): 1.91 (95%CI: 1.89–1.93), p < 0.001, AKI AOR: 1.60 (95%CI:
1.58–1.61), p < 0.001, bleeding AOR: 1.32 (95%CI: 1.30–1.33),
p < 0.001, Pacemaker insertion with AOR 1.48 (95%CI: 1.46–
1.51), p < 0.001, stroke with AOR 1.34 (95%CI: 1.30–1.37),
p < 0.001, vascular complications AOR: 1.15 (95%CI: 1.13–1.18),
p < 0.001, increased length of stay with adjusted MR 1.17 (95%
CI: 1.17–1.18), p < 0.001 and increased cost with adjusted MR
1.11 (95%CI: 1.10–1.11) < 0.001. (Table 3). In subgroup analysis,
similar results were seen in both STEMI and NSTEMI groups
(Supp. Table 4).
Fig. 1. Mortality and complication rates according to CH3A2DS-vasc score.
Table 2
Rates of Mortality and complications, total charges and mean length of stay among ACS with PCI population as per CH3A2DS-VASc score.
Total Low score Medium score High score p-value
N = 252,443 N = 221,462 N = 28,968 N = 2013
All cause In-hospital Mortality 2.5% 1.1% 11.6% 21.5% <0.001
PM insertion 1.9% 1.4% 5.4% 7.5% <0.001
ICD defibrillator placement 0.4% 0.3% 1.1% 1.5% <0.001
All cause bleeding 3.9% 3.1% 8.8% 12.6% <0.001
Post-procedural bleeding 0.5% 0.4% 1.1% 1.7% <0.001
Post-procedural hematoma 1.9% 1.8% 3.1% 4.2% <0.001
Acute post-hemorrhagic anemia 1.9% 1.3% 5.8% 8.9% <0.001
Acute Kidney injury 8.4% 5.8% 25.7% 46.9% <0.001
Stroke 0.9% 0.7% 2.3% 2.5% <0.001
Respiratory failure 6.7% 3.8% 26.5% 42.0% <0.001
Vascular complication 2.2% 2.0% 3.7% 5.0% <0.001
Cost (USD, IQR) 18,238
(13,787–25,327)
17,683
(13,497–24,024)
24,084
(16,931–37,400)
31,146
(21,321–48,002)
<0.001
Length of stay (Days, IQR) 3 (2–4) 2 (2–3) 4 (3–8) 7 (4–11) <0.001
Data are Presented as median (IQR) for continuous measures, and % for categorical measures.
Table 3
Multivariate analysis shows CH3A2DS-Vasc score correlation with study outcomes among study population (A) and among external random sample of 2000 patients from NIS
2015 (B).
A- Study population B- External sample
Adjusted OR / MR 95% CI P value Adjusted OR / MR 95% CI P value
Mortality 1.99 [1.96–2.03] <0.001 2.17 [1.74–2.71] <0.001
Stroke 1.34 [1.30–1.37] <0.001 1.31 [1.01–1.69] 0.041
PMI 1.48 [1.46–1.51] <0.001 1.36 [1.10–1.67] <0.001
ARF 1.91 [1.89–1.93] <0.001 1.96 [1.73–2.21] <0.001
AKI 1.60 [1.58–1.61] <0.001 1.58 [1.38–1.80] <0.001
Bleeding 1.32 [1.30–1.33] <0.001 1.43 [1.21–1.70] <0.001
Vascular 1.15 [1.13–1.17] <0.001 1.14 [0.93–1.40] 0.213
LOS 1.17 [1.17–1.18] <0.001 1.15 [1.11–1.19] <0.001
Cost 1.11 [1.10–1.11] <0.001 1.08 [1.05–1.10] <0.001
* Calculated odd ratio was adjusted for race, gender, components of Elixhauser comorbidity index that had significant association with each outcome at univariate level,
history of prior CABG or PCI, insurance type, year of admission, hospital location, bed-size and teaching status and hospital ownership.
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4. Model validation
The model was internally validated by means of bootstrapping.
After 100 iterations, the mean AUC for the boot strapped samples
was 0.83 (95%CI: 0.82–0.84). The model optimism was estimated
as 0.00 indicating minimal overfitting of the model to the data.
The calibration analysis was on average correct with a
calibration-in-the-large coefficient equal to 0, and the calibration
slope was equal to 1 which correlate with a perfect model (Suppl.
Fig. 5-A). The model was externally validated in a random sample
of 2000 patients derived from NIS database of the year 2015. The
CH3A2DS-VASc score significantly correlated with mortality with
AOR 2.17 (95%CI: 1.74–2.71), p < 0.001 and had high discrimina-
tion ability with AUC of 0.84 (95%CI: 0.77–0.91). In addition, the
score correlated significantly with all other study outcomes except
for vascular complications (Table 3). The calibration analysis was
on average correct with a calibration-in-the-large coefficient equal
to < 0.01, and the calibration slope was equal to 1, which closely
correlates with a ‘‘perfect” model. (Suppl. Fig. 5-B)
5. Discussion
In this study, a modified CHA2DS2-VASc score independently
predicted in-hospital mortality and procedural adverse outcomes
in a linear fashion. Its predictive accuracy is as accurate as more
complex registry models but does not require a computerized algo-
rithm to calculate.
The clinical applicability of this simple-to-calculate risk predic-
tion model allows for early risk stratification of ACS patients
undergoing PCI relying on readily accessible clinical factors to com-
pute a risk score without need for complicated formulas or labora-
tory findings. One of the most important advantages of this score
over other models is its strong predictive power in non-mortality
outcomes, including bleeding, respiratory failure and acute kidney
injury.
Physicians and patients can accurately estimate procedural out-
comes and predict adverse events using easily obtainable clinical
variables with minimal interpretation prior to any invasive proce-
dure. Additionally, the score may be useful as an initial appraisal of
clinical quality, using variables available in non-clinical databases.
Moreover, since these variables are not easily ‘‘gamed”, the score
will have some degree of independence from biased observation.
For these reasons, this CH3A2DS-VASc score provides a simple-to-
calculate algorithm in clinical practice which therefore provides
advantages over more complicated and similarly precise algo-
rithms [1,2].
The CHA2DS2-VASc score was originally validated to predict the
risk of stroke in atrial fibrillation (AF) population, but is actually a
simple calculation predictive of vascular disease. In general,
CHA2DS2-VASc has been utilized with various success rates as a
predictive tool for adverse outcomes in different clinical settings
[9–11]. Despite the high success of CHA2DS2-VASc score in predict-
ing vascular complications and overall adverse effects, its use
among the PCI population has been with limited study popula-
tions. Abugroun et al. investigated the applicability of the
CHA2DS2-VASc score in ACS population in a wide sample derived
from the NIS and concluded that the score correlated with adverse
outcomes. However, when individually analyzed, the original score
components were not all predictive of adverse outcomes. For
instance, hypertension was predictive of lower odds for mortality
and vascular disease had no significant association with adverse
outcomes. Accordingly, the original score had lower discriminative
power with AUC 0.58 [12].
Prediction of in-hospital mortality post PCI has been the subject
of many risk prediction models, including Mayo Clinic Risk Score
(MCRS) and New York State Risk Score (NYSRS). Such models were
to a large extent based on multiple clinical, laboratory and angio-
graphic factors. [13–15]. The published AUC of all of these models
are in the 0.75–0.80 ranges. Despite the lack of laboratory variables
including creatinine in the CH3A2DS-VASc score, the constellation
of variables available in the score seems to be at least equivalent
Fig. 2. A) Receiver operating characteristics (ROC) curve showing the relationship between sensitivity (Y-axis) and 1-specificity (X-axis) in determining the ability of
CH3A2DS-vasc for predicting mortality. The area under the ROC curve (AUC) for CH3A2DS-VASc score is 0.83 (95%C: 0.82–0.84). The highest Youden index (indicated by the
circle symbol) was observed for CH3A2DS-VASc score of  2, B) Intersection between specificity and sensitivity with Youden index point equal to 0.54 with a sensitivity of 77%
and specificity of 77%.
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to the sum of most variables in currently validated risk models. In
addition, CH3A2DS-VASc score is based only on risk factor vari-
ables, which makes it more generalizable and less variable. In par-
ticular, prediction is made without reference to angiographic or PCI
procedural variables, which of course is only known once the pro-
cedure is undertaken. Suppl. Table 5 summarizes the components
and applicability of commonly used risk prediction models in
ACS population. Each component of CH3A2DS-VASc was indepen-
dently predictive of mortality.
Based on the CH3A2DS-VASc we developed a nomogram that
can easily be used on bedside to calculate the adjusted predicted
risk for mortality and adverse outcomes for all ACS patients under-
going PCI. (Fig. 3) To demonstrate the easy applicability of the
score, a 56-year-old male with history of diabetes mellitus, and
heart failure who developed acute coronary event complicated
with hypotension and underwent PCI would have a total CH3A2-
DS-VASc score of 5 which would correlate with adjusted predicted
risk of mortality equal to 12.4%. Risk for ARF 27.3%, stroke 2.3%,
need for PM insertion 6.8%, AKI 19.8%, bleeding 8.8% and vascular
complication of 3.4%. In contrast, a young 40-year-old female with
no prior medical history if admitted for ACS event and underwent
PCI, will have a CH3A2DS-VASc score of only 0 with predicted
adjusted all-cause mortality is 0.3%, ARF 1.2%, Stroke 0.3%, PMI
0.9%, AKI 2%, bleeding event 2.2% and vascular complication 1.7%.
These examples demonstrate the easy applicability of the score
for risk stratification for ACS patients undergoing PCI.
The NYSRS is basically a three-structured model that identified
cardiogenic shock, index hospitalization congestive heart failure
(CHF) and age as important prognostic factors for in-hospital mor-
tality [14]. In the current study, age and CHF are independent pre-
dictors of post PCI in hospital mortality. Since pre-PCI cardiogenic
shock is a well-validated poor outcome predictor, it was similarly
incorporated in the computation of the model. In addition, this
study shows that CH3A2DS-VASc score also predicts bleeding risk,
which was not tested as an outcome in any other risk prediction
models.
Eagle et al (11) tested a simple risk prediction model (GRACE-6-
month) for predicting 6 months risk for mortality in patients with
ACS. Although GRACE-6-month model is generalizable since it was
based on a large population group within GRACE registry, however,
the model was focused towards prediction of long-term mortality
and was not tested against other ACS complications. In addition,
the model used variables including degree of heart failure and car-
diac arrest on admission unlike CH3A2DS-VASc score, which is
mainly based on age and baseline comorbidities and development
of hypotension or cardiogenic shock. Inclusion of cardiac arrest and
new onset heart failure of course raises predictive accuracy of sur-
vival but depends on subjective interpretation and adds mathe-
matical complexity to the calculation of risk.
The ACUITY-PCI (Acute Catheterization and Urgent Intervention
Triage Strategy-Percutaneous Coronary Intervention) Risk Score is
another relatively recent score was developed and validated by
Fig. 3. Nomogram for calculation of adjusted predicted risk for each complication based on each patient calculated CH3A2DS-VASc score.
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Palmerini et al. in 2012. [16] Factors contributed to the ACUITY-PCI
score included insulin-treated diabetes, renal insufficiency; degree
of ST segment elevation, level of cardiac biomarker elevation as
well as the extent of coronary artery disease. While ACUITY-PCI
score predicted adverse events, however, it was only applicable
to patients with unstable angina or NSTEMI. Similar to MCRS, it
included angiographic variables and kidney function as an impor-
tant predictor. The absence of these two variables might be a lim-
itation to the CH3A2DS-VASc score, but it allows the score to be
more useful pre-PCI in order to risk stratify all patients planned
for intervention regardless of the clinical setting or coronary anat-
omy, which can be taken into consideration post procedure.
Most of the other validated risk score for the evaluation of clin-
ical outcome after PCI (clinical SYNTAX, SYNTAX II, National Car-
diovascular Database Registry CathPCI, and the ACEF [age,
creatinine, ejection fraction] model) are less widely used in clinical
daily practice because of the necessity of complex calculation and
substantial inter-observer and intra-observer variability
[17,18,2,19]. Similarly, while TIMI score has proven efficiency on
risk stratification of patients with chest pain with potential ACS,
the score requires a combination of history information together
with EKG and laboratory data, which adds to its complexity.
Orvin et al. demonstrated that the CH3A2DS-VASc score calcu-
lated at the time of the index PCI was accurate in predicting
adverse outcomes, including all-cause mortality and mortality or
myocardial infarction after PCI. [20] However, short-term in-
hospital outcomes were not assessed, and its predictive capability
would be different in each acuity level presentation. In this study,
the modified CHA2DS2-VASc score was demonstrated not just to
predict mortality but also to have high predictive ability for various
short-term adverse outcomes in all ACS patients. It can be used
prospectively, allowing for its wider use and implication to predict
both short and long-term post-PCI outcomes.
The impact of CHA2DS2-VASC score on the likelihood of devel-
oping acute kidney injury has not been well explored. Kurtul
et all described the significant association between the CHA2DS2-
VASC score and contrast-induced nephropathy (CIN) in patients
with ACS who underwent emergent PCI [21]. In this study, a signif-
icant correlation and a linear relation between modified CHA2DS2-
VASc and post PCI acute kidney injury was demonstrated regard-
less of the kidney injury etiology or the urgency of the
intervention.
6. Limitations
The conduct of this analysis has several limitations. The study
was retrospective. The use of ICD codes may have led to inaccura-
cies in estimating diagnosis of certain comorbidities and complica-
tions. To improve the accuracy, a set of ICD codes that were
previously validated in previous studies was utilized. In addition,
the accuracy of the analysis is dependent on the accuracy of the
data collected in the database. Given the limitation of the NIS data-
base and lack of laboratory, radiological information, it was not
possible to compare the predictive results obtained by our model
to other validated risk scores. It is highly recommended to exter-
nally validate this risk model in a patient population and compare
obtained results from the CH3A2DS-VASc score to other widely
used models.
7. Conclusion
CH3A2DS-VASc score is a highly significant predictor of adverse
events, including in-hospital mortality and several other
procedural-related complications, in ACS patients undergoing PCI.
This study supports its applicability as an accurate risk prediction
model for ACS patients undergoing PCI, and could supplant more
complicated models for purposes of quality assurance and clinical
application. One of the most important advantages of this score is
its strong predictive power in non-mortality outcomes, including
bleeding, vascular complications, and acute kidney injury.
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